Clinical data on patients with chronic myeloid leukemia from whom study samples were obtained
| Patient* . | WBC (109/L) . | Marrow metaphases† . | Cells used . | LTC-IC (Ph+/total)‡ . |
|---|---|---|---|---|
| 1 | 110 | 46XX, t(9;9), 25/25 | Blood | 0/61-153 |
| 2 | 540 | 46XY, t(9;22), 25/25 | Marrow | 0/7 |
| 3 | 52 | 46XX, t(9;22), 25/25 | Blood | 17/17 |
| 4 | 650 | 46XX, t(9;22), 25/25 | Blood | 33/33 |
| 5 | 180 | 46XY, t(9;22), 25/25 | Blood | 4/4 |
| 6 | 640 | 46XY, t(9;22), 25/25 | Blood | 2/2 |
| 7 | 520 | 46XY, t(9;22), 30/30 | Blood | 0/121-154 |
| 8 | 230 | 46XY, t(9;22), 30/30 | Blood | 0/31-154 |
| 9 | 400 | 46XY, t(9;22), 30/30 | Blood | 9/101-154 |
| Patient* . | WBC (109/L) . | Marrow metaphases† . | Cells used . | LTC-IC (Ph+/total)‡ . |
|---|---|---|---|---|
| 1 | 110 | 46XX, t(9;9), 25/25 | Blood | 0/61-153 |
| 2 | 540 | 46XY, t(9;22), 25/25 | Marrow | 0/7 |
| 3 | 52 | 46XX, t(9;22), 25/25 | Blood | 17/17 |
| 4 | 650 | 46XX, t(9;22), 25/25 | Blood | 33/33 |
| 5 | 180 | 46XY, t(9;22), 25/25 | Blood | 4/4 |
| 6 | 640 | 46XY, t(9;22), 25/25 | Blood | 2/2 |
| 7 | 520 | 46XY, t(9;22), 30/30 | Blood | 0/121-154 |
| 8 | 230 | 46XY, t(9;22), 30/30 | Blood | 0/31-154 |
| 9 | 400 | 46XY, t(9;22), 30/30 | Blood | 9/101-154 |
WBC indicates white blood cell count; LTC-IC, long-term-culture–initiating cells; Ph+, Philadelphia chromosome positive.
Patient samples 1 to 6 were described previously.24
Numbers after the karyotype indicate the number of metaphases with that karyotype of the total number analyzed at the time the sample was obtained.
Values are the number of LTC-IC–derived Ph+colony-forming cells (CFCs) detected and the total number of LTC-IC–derived CFCs for which 2 metaphases per colony were obtained. LTC-IC and CFCs were assayed as described previously.24
Based on the presence of t(9;9).
Positive for BCR-ABL on assessment with fluorescent in situ hybridization.